MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR

Sanjib Chaudhary, Muthamil Iniyan Appadurai, Shailendra Kumar Maurya, Palanisamy Nallasamy, Saravanakumar Marimuthu, Ashu Shah, Pranita Atri, Chirravuri Venkata Ramakanth, Subodh M. Lele, Parthasarathy Seshacharyulu, Moorthy P. Ponnusamy, Mohd W. Nasser, Apar Kishor Ganti, Surinder K. Batra, Imayavaramban Lakshmanan

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background: Triple-negative breast cancer (TNBC) is highly aggressive with an increased metastatic incidence compared to other breast cancer subtypes. However, due to the absence of clinically reliable biomarkers and targeted therapy in TNBC, outcomes are suboptimal. Hence, there is an urgent need to understand biological mechanisms that lead to identifying novel therapeutic targets for managing metastatic TNBC. Methods: The clinical significance of MUC16 and ELAVL1 or Hu antigen R (HuR) was examined using breast cancer TCGA data. Microarray was performed on MUC16 knockdown and scramble TNBC cells and MUC16-associated genes were identified using RNA immunoprecipitation and metastatic cDNA array. Metastatic properties of MUC16 were evaluated using tail vein experiment. MUC16 and HuR downstream pathways were confirmed by ectopic overexpression of MUC16-carboxyl-terminal (MUC16-Cter), HuR and cMyc as well as HuR inhibitors (MS-444 and CMLD-2) in TNBC cells. Results: MUC16 was highly expressed in TNBC and correlated with its target HuR. Depletion of MUC16 showed decreased invasion, migration, and colony formation abilities of human and mouse TNBC cells. Mice injected with MUC16 depleted cells were less likely to develop lung metastasis (P = 0.001). Notably, MUC16 and HuR were highly expressed in the lung tropic TNBC cells and lung metastases. Mechanistically, we identified cMyc as a HuR target in TNBC using RNA immunoprecipitation and metastatic cDNA array. Furthermore, MUC16 knockdown and pharmacological inhibition of HuR (MS-444 and CMLD-2) in TNBC cells showed a reduction in cMyc expression. MUC16-Cter or HuR overexpression models indicated MUC16/HuR/cMyc axis in TNBC cell migration. Conclusions: Our study identified MUC16 as a TNBC lung metastasis promoter that acts through HuR/cMyc axis. This study will form the basis of future studies to evaluate the targeting of both MUC16 and HuR in TNBC patients.

Original languageEnglish (US)
Article number25
JournalBreast Cancer Research
Issue number1
StatePublished - Dec 2023


  • ELAVL1/HuR
  • MMP1
  • MMP3
  • Metastasis
  • TNBC
  • UC16
  • YB1
  • YBX-1
  • cMyc

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR'. Together they form a unique fingerprint.

Cite this